A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi

Vaccine

Volumn 30, Issue 23, 2012, Pages 3405-3412

  Lu, Ying Jie ^a   Zhang, Fan ^a   Sayeed, Sabina ^a   Thompson, Claudette M ^b   Szu, Shousun ^c   Anderson, Porter W ^a   Malley, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Salmonella typhi; Streptococcus pneumoniae; Vaccine; Vi polysaccharide

Indexed keywords

ADHESIN; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; GLUCOSE 6 PHOSPHATE ISOMERASE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; PNEUMOCOCCAL PROTECTIVE PROTEIN A; PNEUMOCOCCAL SURFACE ADHESIN A; PNEUMOCOCCUS TYPHOID CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL COLONIZATION; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NASOPHARYNX; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; SALMONELLA TYPHI; SEPSIS; SERUM BACTERICIDAL ACTIVITY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TH17 CELL; TYPHOID FEVER;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SALMONELLA TYPHI; SEPSIS; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE;

EID: 84859873240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.039     Document Type: Article

References (55)

1. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(May (5)):346-353.
2. Lin F.Y., Vo A.H., Phan V.B., Nguyen T.T., Bryla D., Tran C.T., et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000, 62(May (5)):644-648.
3. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., et al. Typhoid fever in children aged less than 5 years. Lancet 1999, 354(August (9180)):734-737.
4. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
5. Robbins J.D., Robbins J.B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984, 150(September (3)):436-449.
6. Raffatellu M., Chessa D., Wilson R.P., Tukel C., Akcelik M., Baumler A.J. Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. Infect Immun 2006, 74(January (1)):19-27.
7. Wilson R.P., Winter S.E., Spees A.M., Winter M.G., Nishimori J.H., Sanchez J.F., et al. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect Immun 2010, 79(February (2)):830-837.
8. Yang H.H., Wu C.G., Xie G.Z., Gu Q.W., Wang B.R., Wang L.Y., et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001, 79(7):625-631.
9. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., et al. The vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18(May (5)):730-735.
10. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(April (17)):1263-1269.
11. Micoli F., Rondini S., Pisoni I., Proietti D., Berti F., Costantino P., et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella typhi. Vaccine 2011, 29(January (4)):712-720.
12. Haeuw J.F., Libon C., Zanna L., Goetsch L., Champion T., Nguyen T.N., et al. Physico-chemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA. Dev Biol (Basel) 2000, 103:245-250.
13. Hale C., Bowe F., Pickard D., Clare S., Haeuw J.F., Powers U., et al. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. Vaccine 2006, 24(May (20)):4312-4320.
14. Szu S.C., Li X.R., Schneerson R., Vickers J.H., Bryla D., Robbins J.B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun 1989, 57(December (12)):3823-3827.
15. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166(November (5)):1510-1524.
16. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62(October (10)):4440-4444.
17. Rondini S., Micoli F., Lanzilao L., Hale C., Saul A.J., Martin L.B. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol 2011, 18(March (3)):460-468.
18. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17(January (1)):73-79.
19. Shah N.K. Indian conjugate Vi typhoid vaccine: do we have enough evidence?. Indian Pediatr 2009, 46(February (2)):181-182.
20. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(October (Suppl. 2)):S22-S27.
21. Levine M.M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990, 336(October (8720)):891-894.
22. Prymula R., Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(November (11)):1479-1500.
23. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007, 25(March (12)):2194-2212.
24. Chuck A.W., Jacobs P., Tyrrell G., Kellner J.D. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010, 28(July (33)):5485-5490.
25. Johnson H.L., Deloria-Knoll M., Levine O.S., Stoszek S.K., Freimanis Hance L., Reithinger R., et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010, 7(October (10)):e1000348.
26. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(April (9807)):1962-1973.
27. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006, 32(3):139-153.
28. Swiatlo E., Ware D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol 2003, 38(August (1)):1-7.
29. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000, 18(February (16)):1707-1711.
30. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011, 23(June (3)):407-413.
31. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4(9):e1000159.
32. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005, 102(March (3)):4848-4853.
33. van Rossum A.M., Lysenko E.S., Weiser J.N. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 2005, 73(November (11)):7718-7726.
34. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., Flechtner J.B., et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9(February (2)):158-165.
35. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med 2010, 88(February (2)):135-142.
36. Lu Y.J., Forte S., Thompson C.M., Anderson P.W., Malley R. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 2009, 77(May (5)):2076-2083.
37. Lu Y.J., Leite L., Goncalves V.M., Dias Wde O., Liberman C., Fratelli F., et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28(November (47)):7468-7475.
38. Lu Y.J., Yadav P., Clements J.D., Forte S., Srivastava A., Thompson C.M., et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 2010, 17(June (6)):1005-1012.
39. Vintini E., Villena J., Alvarez S., Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 2009, 159(March (3)):351-362.
40. Green B.A., Zhang Y., Masi A.W., Barniak V., Wetherell M., Smith R.P., et al. PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 2005, 73(February (2)):981-989.
41. Ling E., Feldman G., Portnoi M., Dagan R., Overweg K., Mulholland F., et al. Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse. Clin Exp Immunol 2004, 138(November (2)):290-298.
42. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180(August (1)):249-261.
43. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001, 69(August (8)):4870-4873.
44. Malley R., Srivastava A., Lipsitch M., Thompson C.M., Watkins C., Tzianabos A., et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 2006, 74(April (4)):2187-2195.
45. CDC Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54(September (36)):893-897.
46. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119(July (7)):1899-1909.
47. Karlsson C., Jansson P.E., Skov Sorensen U.B. The pneumococcal common antigen C-polysaccharide occurs in different forms. Mono-substituted or di-substituted with phosphocholine. Eur J Biochem 1999, 265(November (3)):1091-1097.
48. Wallick S., Claflin J.L., Briles D.E. Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol 1983, 130(June (6)):2871-2875.
49. Yother J., Forman C., Gray B.M., Briles D.E. Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun 1982, 36(1):184-188.
50. Briles D.E., Nahm M., Schroer K., Davie J., Baker P., Kearney J., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med 1981, 153(3):694-705.
51. Mai N.L., Phan V.B., Vo A.H., Tran C.T., Lin F.Y., Bryla D.A., et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003, 349(October (14)):1390-1391.
52. Kossaczka Z., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999, 67(November (11)):5806-5810.
53. Roe J.H. The determination of sugar in blood and spinal fluid with anthrone reagent. J Biol Chem 1955, 212(January (1)):335-343.
54. Azze R.F., Rodriguez J.C., Iniesta M.G., Marchena X.R., Alfonso V.M., Padron F.T. Immunogenicity of a new Salmonella typhi Vi polysaccharide vaccine-vax-TyVi-in Cuban school children and teenagers. Vaccine 2003, 21(June (21-22)):2758-2760.
55. Gondwe E.N., Molyneux M.E., Goodall M., Graham S.M., Mastroeni P., Drayson M.T., et al. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci USA 2010, 107(February (7)):3070-3075.